文献速递甲状腺疾病

促甲状腺激素抑制治疗用于低危小甲状腺癌:倾向评分匹配队列研究

Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
PubMed 文献 · Thyroid · 2017-08-08

这项回顾性倾向评分匹配队列研究纳入2002至2008年接受肺叶切除术的446例分化型甲状腺癌(DTC)患者,比较接受与未接受促甲状腺激素抑制治疗(TST)者的无病生存和动态危险分层。中位随访8.6年,两组无病生存无显著差异(p=0.63),复发10例(2.7%),治疗反应优良比例相近。结论认为TST未改善低危小DTC患者临床结局,无甲状腺功能减退证据者不需左甲状腺素。

要点

  • TST组约74%、无TST组11%患者血清TSH被抑制至<2 mIU/L。
  • 中位随访8.6年,两组无病生存无显著差异(p=0.63),复发10例(2.7%)。
  • 低危小DTC肺叶切除后TST未改善结局,无甲状腺功能减退证据者不需左甲状腺素。

核心结论

  • TST未改善低危小DTC患者的临床结局,血清TSH水平与复发无关,肺叶切除的低危患者行TSH抑制未见临床获益,无甲状腺功能减退证据者不需左甲状腺素。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,纳入2002至2008年接受肺叶切除术的DTC患者446例,分为TST组与无TST组。

主要发现

  • TST组约74%、无TST组11%患者血清TSH被抑制至<2 mIU/L,中位随访8.6年。
  • 随访期间10例(2.7%)复发,两组无病生存无显著差异(p=0.63)。
  • 治疗反应优良比例TST组65.2% vs 无TST组64.4%,两者相近。
  • 生化反应不完全者TST组17.2% vs 无TST组9.4%。
  • 按血清TSH水平比较,两组无病生存仍无显著差异(p=0.57)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyrotropin (TSH) suppression has improved the clinical outcomes of patients with differentiated thyroid cancer (DTC). However, the efficacy of TSH suppressive therapy (TST) is unclear in patients with low-risk DTC. This study aimed to evaluate the efficacy of TST and optimal TSH levels of patients with low-risk DTC. METHODS: This retrospective propensity score-matched cohort study included DTC patients (n = 446) who underwent lobectomy from 2002 to 2008 with or without TST (TST group and No-TST group). Disease-free survival (DFS) and dynamic risk stratification were compared between both groups using serum TSH levels. RESULTS: Approximately 74% of TST patients and 11% of No-TST patients had suppressed serum TSH levels (<2 mIU/L). The median follow-up period was 8.6 years. During follow-up, the disease recurred in 10 (2.7%) patients, with no significant difference in DFS between the groups (p = 0.63). The proportion of patients with excellent treatment response was similar between the TST (65.2%) and No-TST (64.4%) groups. Incomplete biochemical response was noted in 17.2% of the TST group patients and 9.4% of the No-TST group patients. No significant difference was observed in the DFS between both groups by comparing serum TSH level (p = 0.57). CONCLUSIONS: TST did not improve clinical outcomes, and serum TSH levels were not associated with recurrence in patients with low-risk small DTC. No clinical benefits were shown for TSH suppression in low-risk patients who underwent lobectomy. Thus, levothyroxine is not necessary for patients without evidence of hypothyroidism.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Park S, Kim WG, Han M, et al. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study. Thyroid. 2017. PMID: 28699428. doi:10.1089/thy.2017.0177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。